HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Vinorelbine Tartrate

HCID 11607738
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
125317-39-7
Standard SMILES
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)[C@H](O)[C@@H](O)C(=O)O.O=C(O)[C@H](O)[C@@H](O)C(=O)O
InChIKey
CILBMBUYJCWATM-PYGJLNRPSA-N
Molecular formula
C53H66N4O20
Average molar mass
1,079.1 g/mol
Monoisotopic mass
1,078.42704051

Overview

Vinorelbine Tartrate is the ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent. (NCI04)

Names & identifiers

Preferred name
Vinorelbine Tartrate
IUPAC
bis((2R,3R)-2,3-dihydroxybutanedioic acid);methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
English name
Vinorelbine tartrate
Molecular formula
C53H66N4O20
Molecular weight
1079.11

Names & synonyms

Vinorelbine tartrateVinorelbine ditartrateKW-2307Vinorelbine liposomal253GQW851QVinorelbine (as tartrate)Vinorelbine BitartrateLiposomal vinorelbine tartrateVinorelbine tartrate (1:2)TLC178TLC-178Eunades
Show more names
NAVELBINENVBVinorelbin Tartratec’-norvincaleukoblastine,3’,4’-didehydro-4’-dioxy-,(r-(r*,r*))-2,3-dihydroxyVINORELBINE TARTRATE USP STANDARD3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartrate(2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylicacidmethylester
DTXSID5047825Nor-5'-anhydrovinblastine ditartrateC'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:2) (salt)Vinorelbine DitartarateNSC608210CHEBI:32296BiovelbinNavelbine ditartrate

Properties

Computed structural properties

Topological polar surface area
364 Ų
Hydrogen bond donors
10
Hydrogen bond acceptors
23
Rotatable bonds
16
Heavy atoms
77
Formal charge
0
Complexity
1,820

Experimental & physicochemical properties

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

Melting point
181 · 181-183°C
storage temp.
2 · 2-8°C
solubility
2 O: · H2O: 10 mg/mL
form
powder
color
off-white
Water Solubility
2 O: · H2O: 10mg/mL
Stability
Light Sensitive, Temperature Sensitive
InChIKey
PMDHUNWDGZSEMN-WTUOTUPFSA-N
CAS DataBase Reference
125317 · 125317-39-7(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
vinorelbine tartrate
FDA UNII
253 GQW851Q · 253GQW851Q
NCI Drug Dictionary
vinorelbine tartrate

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (88.9%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P264, P264+P265, P270, P280, P301+P316, P302+P352, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 63 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 2 (88.9%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Vinorelbine tartrate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Safety data

PPE
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
wgk
3
ridadr
UN 1544PSN1 6.1 / PGII
hs_code
29339900
risk_code
43
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xi
safety_code
26-36

Chemistry & industry

Pharmacology

MeSH Pharmacological Classification · 2 items

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.

Uses & manufacturing

UsesUse (kg) in USA (2002): 3
Applications · 2 items

UsesVinorelbine Bitartrate is an antineoplastic.

General DescriptionVinorelbine ditartrate is available in 1- and 5-mL vials at aconcentration of 10 mg/mL for IV use. It is FDA approvedfor the treatment of NSCLC. The agent has also been usedin treating metastatic breast cancer, cervical cancer, uterinecancer, and lung cancer especially in older patients or thosewith physical difficulties. Vinorelbine is the most lipophilicof the vinca alkaloids because of modifications of thecatharanthine ring system and dehydration of the piperidinering. This allows the agent to be quickly taken up into cellsincluding lung tissue where concentrations are 300-foldhigher than plasma concentrations. This is 3 to 13 timeshigher than the lung concentrations seen with vincristine.The agent is highly protein bound (80%–91%) and metabolizedby CYP3A. The major metabolite seen is the 4-Odesacetylderivative, which is equally active with the parentbut only formed in small quantities. The agent is eliminatedprimarily (33%–88%) in the bile with some appearing inthe urine (16%–30%). The elimination half-life is 27 to43 hours. The toxicities seen for vinorelbine includemyelosuppression, which is dose limiting but ceases upondiscontinuation of drug. This is most commonly seen as aneutropenia, and patient’s neutrophil count should be monitoredprior to and during therapy to decrease the chanceof infection. Additional toxicities include nausea/vomiting,elevation of liver function tests, alopecia, generalized fatigue,and inappropriate secretion of antidiuretic hormone.Neurotoxicity is seen with vinorelbine but occurs to a lesserdegree compared with other vinca alkaloids because of itsdecreased affinity for axonal microtubules.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
125317-39-7
PubChem CID
11607738
DTXSID
DTXSID5047825
ChEMBL
CHEMBL538943
UNII
253GQW851Q
EC Number
639-264-2
UNSPSC Code
12352200 · 12352200
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
317 · H317
Precautionary statements
280 · P280
PPE
95 · dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Codes
Xi
Risk Statements
43 · 43
Safety Statements
26 · 26-36
RIDADR
1544 PSN1 · UN 1544PSN1 6.1 / PGII
WGK Germany
3 · 3
HS Code
29339900 · 29339900
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
1 · Skin Sens. 1
Storage Class
11 - Combustible Solids
Hazard statements
H317
Hazard Classifications
Skin Sens. 1
Precautionary statements
P280

Upstream & downstream products

Downstream products

Vinorelbine

Additional notes

DefinitionChEBI: The L-(+)-tartrate salt of vinorelbine.